107 Results for "

complement inhibitors

" in MedChemExpress (MCE) Product Catalog:
Products (107)

107 Results for "complement inhibitors" in MCE Product Catalog:

Cat. No.: HY-P990955
CAS No.: 2839652-75-2
Synonyms: ADX-097

Target:  

CD3 Complement System

Research Areas:  

Inflammation/Immunology

Ebribafusp alfa (ADX-097) comprising a humanized anti-C3d monoclonal antibody linked to two moieties of the first five consensus repeats of factor H (fH1-5). Ebribafusp alfa binds C3d and related fragments, catalyzes AP convertase dissociation, acts as a factor I co-factor for C3b cleavage, and delivers fH1-5 moieties to C3d-deposited tissues for local complement inhibition without systemic blockade. Ebribafusp alfa reduces glomerular C3 deposition, proteinuria, urine albumin-creatinine ratios, and urine soluble C5b-9 levels, preserves podocyte foot-process architecture, inhibits skin complement activation, and localizes to UVB-damaged primate skin. Ebribafusp alfa can be used for the research of membranous nephropathy, bullous pemphigoid, discoid lupus erythematosus, C3 glomerulopathy, IgA nephropathy, and lupus nephritis .
loading...
    loading...
Cat. No.: HY-184031
CAS No.: 133-65-3
Synonyms: Solapsone; Sulfetrone
Research Areas:  

Cancer

Solasulfone (Solapsone; Sulfetrone) is an inhibitor of complement protein C1q and β-lactamase. Solasulfone also acts as a chemotherapeutic agent and can be used in cancer research .
loading...
    loading...
Cat. No.: HY-P992456
Target:  

Complement System

SAR-443809 is a monoclonal antibody targeting complement factor Bb that inhibits the alternative complement pathway. SAR-443809 blocks the cleavage of C3 and factor B via selective binding to the activated form factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for research on hematological and renal disorders mediated by abnormal alternative complement pathway activity .
loading...
    loading...
Cat. No.: HY-102034R
CAS No.: 1386455-76-0
Complement factor D-IN-1 (Standard) is the analytical standard of Complement factor D-IN-1 (HY-102034). This product is intended for research and analytical applications. Complement factor D-IN-1 is a potent and selective small-molecule reversible factor d inhibitor, with IC50s of 0.006 and 0.05 μM in FD Thioesterolytic Fluorescent Assay and a MAC Deposition Assay, respectively.
loading...
    loading...
Cat. No.: HY-P991022
CAS No.: 2842046-67-5
Synonyms: NM8074

Target:  

Complement System

Research Areas:  

Endocrinology

Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces C3b deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy .
loading...
    loading...
Cat. No.: HY-P3252AS
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
loading...
    loading...
Cat. No.: HY-127105B
CAS No.: 1644670-38-1
Synonyms: LNP023 TFA
Iptacopan (LNP023) TFA is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan TFA exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan TFA can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
loading...
    loading...
Cat. No.: HY-P991954

Target:  

Complement System Syk

Research Areas:  

Inflammation/Immunology Cancer

GT103 is a human-derived monoclonal antibody targeting complement factor H (CFH). GT103 binds to a conformationally distinct epitope of CFH on tumor cells. GT103 activates the classical complement pathway, induces complement-dependent cytotoxicity, and triggers antibody-dependent cellular phagocytosis (ADCP) of tumor cells. GT103 increases calreticulin translocation to tumor cell plasma membranes. GT103 mediates B-cell activation via Syk kinase phosphorylation. GT103 inhibits tumor growth and metastasis in animal models. GT103 can be used for the research of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-N19128
CAS No.: 1476801-10-1
Pulchinenoside J is a lupane-type triterpenoid saponin and a complement system inhibitor that acts via the classical pathway. Pulchinenoside J can be isolated from the roots of Pulsatilla chinensis .
loading...
    loading...
Cat. No.: HY-17627S1
CAS No.: 2316781-85-6
Synonyms: CCX168-d4
Avacopan-d4 (CCX168-d4) is the deuterium labeled Avacopan (HY-17627). Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
loading...
    loading...
Cat. No.: HY-P992463

Target:  

Ser/Thr Protease

Research Areas:  

Endocrinology

SHR-2010 is a fully humanized monoclonal antibody targeting MASP-2. SHR-2010 selectively inhibits lectin pathway activation without affecting classical or alternative complement pathways. SHR-2010 can be used for the research of IgA nephropathy .
loading...
    loading...
Cat. No.: HY-N7955
CAS No.: 372096-70-3
23-O-Acetylcimigenol-3-O-α-L-arabinopyranside (Compound 1) is a triterpene glycoside found in the rhizomes of Cimicifuga heracleifolia.23-O-Acetylcimigenol-3-O-α-L-arabinopyranside does not inhibit the classical pathway of the complement system .
loading...
    loading...
Cat. No.: HY-P992111
CAS No.: 3058391-18-4
Synonyms: UCB4594

Target:  

MHC

Research Areas:  

Cancer

Elfritatug (UCB4594) is a humanized monoclonal antibody targeting human leukocyte antigen-G (HLA-G). By binding to HLA-G on the surface of tumor cells, Elfritatug blocks its immunosuppressive effect, thereby enhancing the body's immune response against tumors .
loading...
    loading...
Cat. No.: HY-P992512
Target:  

Complement System

Research Areas:  

Neurological Disease

ANX-M1 Mouse IgG1 is a brain-penetrant C1q inhibitor. ANX-M1 Mouse IgG1 blocks classical complement pathway activation, reduces C1q concentrations in brain and plasma, and inhibits microglia-mediated synapse engulfment. ANX-M1 Mouse IgG1 can be used for the research of Huntington's disease, Alzheimer's disease, retinopathy and neuropathic pain .
loading...
    loading...
Cat. No.: HY-N17326
CAS No.: 242794-72-5
Ilekudinol B is an inhibitor of ACAT and PTP1B, with an IC50 of 5.3 μM and a Ki of 11.6 μM against human PTP1B. Ilekudinol B inhibits the classical pathway of the complement system, with an IC50 of 51 μM. Ilekudinol B inhibits TNF-α-induced cellular IL-8 secretion, promotes glucose uptake in skeletal muscle myotubes, and acts as an insulin mimetic and insulin sensitizer. Ilekudinol B can be used in research related to type 2 diabetes, obesity, and inflammatory diseases .
loading...
    loading...
Cat. No.: HY-P991791

Target:  

Integrin

Research Areas:  

Inflammation/Immunology

Anti-Rat CD11b/c Antibody (OX42) reacts with rat CD11b and CD11c. Anti-Rat CD11b/c Antibody (OX42) inhibits complement-mediated rosettes formation and leukocyte migration in vitro, and blocks the binding of iC3b to CR3 in vitro and in vivo. Recommend Isotype Controls: Mouse IgG2a kappa, Isotype Control (HY-P99978) .
loading...
    loading...
Cat. No.: HY-P991869
Synonyms: AQmabAM; rAb-53

Target:  

Aquaporin

Research Areas:  

Neurological Disease

Aquaporumab (AQmabAM) is an engineered human monoclonal IgG antibody. Aquaporumab is a selective inhibitor of aquaporin 4 (AQP4), binding tightly to AQP4 and competitively displacing AQP4-IgG from serum [1][2]. Aquaporumab significantly reduces neuromyelitis optica lesions in spinal cord slice cultures and in mice receiving intracerebral injection of AQP4-IgG and complement [1][2]. Aquaporumab can be used for research on neuromyelitis optica spectrum disorders [1][2]."}
loading...
    loading...
Cat. No.: HY-P992142
CAS No.: 3050549-24-8
Synonyms: ANX-007

Target:  

Complement System

Vonaprument (ANX-007) is an intravitreally injected C1q antibody fragment (with a molecular weight of approximately 48 kDa) and a human monoclonal antibody. Vonaprument inhibits the activation of the classical complement cascade by specifically recognizing the globular head of C1q and blocking substrate binding. After intravitreal injection, Vonaprument distributes to the retina, choroid and optic nerve, and achieves complete C1q target binding in the aqueous humor and retinal tissues. Vonaprument can be used in research related to neurodegenerative eye diseases such as age-related macular degeneration and glaucoma .
loading...
    loading...
Cat. No.: HY-181040
CAS No.: 3049710-19-9
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Factor B-IN-8 (Compound (3R ,4R )-15) is a potent, selective and orally active factor B inhibitor with an IC50 of 10.2 nM. Factor B-IN-8 can effectively inhibit the binding of factor B to C3b and the subsequent formation of C3 convertase (C3bBb). Factor B-IN-8 can inhibit the deposition of membrane attack complex (MAC) mediated by alternativepathway with an IC50 of 59.3 nM. Factor B-IN-8 can reduce the cleavage of factor B protein and decrease the deposition of complement C3d in the glomeruli and renal tubules. Factor B-IN-8 can be used for researches of arthritis and paroxysmal nocturnal hemoglobinuria (PNH) .
loading...
    loading...
Cat. No.: HY-P992361

Research Areas:  

Cancer

HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3 + Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors .
loading...
    loading...